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The United Kingdom Joint Committee on Vaccination and Immunisation provides advice to theMinisters
of Health on all aspects of vaccination. Under recent legislation a recommendation from the Committee
confers the right to the vaccine concerned to the population of England Wales. A critical aspect of both
advice and recommendations is that the vaccination is shown to reach a cost-effectiveness threshold.
This usually requires sophisticated mathematical modelling and economics.
© 2010 Elsevier Ltd.
1. Description and background
The Joint Committee on Vaccination and Immunisation (JCVI)
is a Standing Advisory Committee. It was originally an advisory
board for polio immunisation that became the JCVI in 1963. The
JCVI in its current statutory form was established by the National
Health Service (NHS) (Standing Advisory Committees) Order 1981
(SI 1981/597) made under what are now provisions of the NHS Act
2006 and the NHS (Wales) Act 2006. Statutory functions of the JCVI
extend to England and Wales.
The committee currently consists of 17 members with each
member representing a different professional discipline although
all professional members must have speciﬁc knowledge of vacci-
nation. Thus there are a general hospital paediatrician, a paediatric
neurologist, an adult infectious disease physician, a paediatrician
with interest in infectious disease, a community paediatrician, a
nurse (currently two), a public health physician, a general prac-
titioner, an epidemiologist, an immunologist, a bacteriologist, a
virologist and a lay person plus a member from each of Scotland
(a public health physician), Wales (a public health physician) and
Northern Ireland (a paediatrician). An economist is currently being
recruited because of the increasing importance of economic evalu-
ation. Members are recruited through national advertisement and
the selection made by an independent body, the Appointments
Commission. The Chairman is selected by committee members
from amongst themselves. The lengths of appointments are deter-
Abbreviations: HPA, Health Protection Agency; JCVI, Joint Committee on Vacci-
nation and Immunisation; MHRA, Medicines and Health Care Regulatory Agency;
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mined using the Code of Practice from the Commissioner for Public
Appointments. The Chairman and members are not remunerated
but payment of expenses is made for attendance at meetings. The
Committeemeets three timesperyearundernormal circumstances
although two additional meetings to discuss pandemic inﬂuenza
have been necessary this year (2009).
The secretariat to the committee is provided by the Immunisa-
tion section of the Department of Health. The Agenda is agreed
between the Chairman and the secretariat and includes issues
raised by members, through letters to the committee and by the
Ministers of Health.
2. Role of the committee in policy formulation
Until recently the advice that the committee provided to Min-
isters was just that advice. However, relevant provisions of the
NHS Constitution were enacted via Regulations which came into
force on 1st April 2009. The Regulations specify that the public in
England have the right to receive vaccinations as speciﬁed in any
“Recommendation” of the committee that relates to a newnational
vaccination programme or to changes to an existing national vac-
cination programme. The Recommendation must be on a question
speciﬁcally referred by the Secretary of State, be based on an
assessment which demonstrates cost-effectiveness and not relate
to travel or occupational health. All other decisions of the JCVI are
merely advisory.
3. Terms of reference and processes of meetings
The JCVI adopted new terms of reference at their meeting on
17th June 2009. They are (in part): “To advise the Secretary of State
for Health and Welsh Ministers on matters relating to communi-
cable diseases, preventable and potentially preventable through
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vaccination and immunisation”. The JCVI’s statutory functions do
not relate to Scotland or Northern Ireland although their Minis-
ters may choose to accept its advice. The role of the committee in
ultimate decision making is discussed further below.
There is a JCVI code of practice for members which is pub-
lished on the committee website (http://www.dh.gov.uk/ab/JCVI/
index.htm), however a revised Code of Practice and JCVI Protocol
are in development. At each meeting all members must declare
any potential conﬂicts of interest and a register of such interests is
maintained and published on thewebsite. These potential conﬂicts
are classiﬁed as personal or non-personal. Personal conﬂicts arise
where the individualhas themselves receivedmoney for consultan-
cies with industry, fee paid work where industry pays the member
in cash or kind or where the members holds shares in a company
(actual sums of money are not given in the declaration). Indus-
try here refers to companies, partnerships of individuals who are
involved with the manufacture, promotion or supply of vaccines,
trade associations representing such companies or similar bodies
engaged in research and development or marketing of products
under consideration by the committee. Non-personal conﬂicts are
those where payment beneﬁts a department for which a member
is responsible but is not received by the member personally. The
usual examples are industry funded grants and fellowships, pay-
ments of salaries for staff or sponsorship of research by industry.
These are all considered relevant if they occurred in the 12months
prior to the meeting or are planned to occur in the future.
These potential conﬂicts of interest are further divided into
those that are speciﬁc to the vaccine or product under discussion
and non-speciﬁcwhere they relate to a different vaccine or product
made by the relevant company.
During the meeting members with a personal speciﬁc interest
are asked to leave the roomduring discussion and decisionmaking.
Those with a personal non-speciﬁc interest take part in the dis-
cussion but not in the decision making. Those with non-personal
speciﬁc interests can participate in the discussion, unless the chair-
man rules otherwise but do not take part in decision making and
thosemembers with non-personal, non-speciﬁc interests take part
in the discussion and decision making.
The committee carries out horizon scanning—mainly aimed at
identifying vaccines which are likely to be licensed in the next 3–5
years. This allows them to advise on the development of appro-
priate surveillance in advance of licensure and any research which
may be needed to facilitate decision making. For example if costs
of a potentially vaccine preventable illness need to be collected or
the current burden of disease to be estimated.
The committee frequently has to consider changes to the vac-
cination schedules—for example where new evidence suggests a
change in dose interval or timing would be beneﬁcial. Similarly
there may be changes in indications for vaccines due to new evi-
dence and the committee provides advice on this. As part of its
work the committee considers data on vaccine coverage and may
provide advice in relation to this. However the committee has no
role in running the immunisation programmes.
In addition the committee reviews informationonpotential vac-
cine adverse events including published studies from the global
literature, reports of studies speciﬁcally carried out in the United
Kingdom (UK), the routine surveillance of adverse reactions car-
ried out by the Health Protection Agency (HPA) and reports from
the surveillance system of the Medicines and Healthcare Regula-
toryAgency (MHRA). The committeeuses this information toweigh
risks and beneﬁts in its decision making but has no regulatory role
in relation to vaccines (see case study on the Hib booster campaign
in Table 1).
The work of the committee which attracts the most attention
is related to newly licensed vaccines. This is discussed in the next
two sections.
Table 1
Haemophilus inﬂuenzae type b (Hib) booster campaign 2007.
1. Routine surveillance showed an increase in Hib disease greater than
expected in children aged 3–4 years and over
2. The committee considered adding a booster dose to the pre-school
Diphtheria-Pertussis-Tetanus (DPT) dose
3. It was estimated that 50 cases of disease and 2 deaths could be
prevented but the cost-effectiveness exceeded the threshold
4. Nevertheless the committee advised that a booster campaign should
be conducted
5. This advice was accepted by the Government
6. However it necessitated that for the period of the campaign the
vaccine used was changed from Diphtheria-Tetanus-acellular
Pertussis (DTaP)/inactivated polio vaccine (IPV) or reduced dose
diphtheria-Tetanus-acellular Pertussis (dTaP)/IPV to DTaP/IPV/Hib
or for older children Hib-Meningococcal C vaccine
7. This required the “off-label” use of these vaccines (i.e. outside the
ages that they are licensed for
8. On the basis of evidence the committee recommended this and that
the evidence was published on the website (http://www.dh.gov.uk/
prod consum dh/groups/dh digitalassets/@dh/@ab/documents/digitalasset/
dh 094741.pdf)
4. Development of recommendations and basis for decision
making
Where a new vaccine or an alteration to the routine schedule
is to be discussed by the main committee the ﬁrst step taken is
to establish an expert sub-committee. This has a member of the
main JCVI as the chairman and any additional members of the
main committeewho have particular expertise relevant to the vac-
cination being considered. Other members of this sub-committee
are then recruited with relevant expertise from academia, govern-
ment agencies, etc. This is done to ensure that all of the necessary
disciplines are represented—e.g. laboratory science, clinical, epi-
demiological, modelling and economics. These sub-committee
members also have to make declarations of potential conﬂicts of
interest and the same procedures in handling these apply. The
sub-committee will then meet perhaps two or three times to
review the evidence available and where appropriate to provide
advice on parameters for modelling and economics. It will for-
mulate advice on a recommendation which is then passed to the
main committee. In the meantime any cost-effectiveness mod-
elling that has been necessary will go out to peer review. This
review is done by national and international experts—both in
economic modelling and in the disease speciﬁc area. These ref-
eree reports are then sent to the group who carried out the
cost-effectiveness estimation and they respond—either with a
rebuttal of the comments or with a modiﬁcation of the esti-
mates.
All of these reports then come to the main committee. It
then chooses to accept or modify the sub-committee recom-
mendation. On occasion it may require a further modiﬁcation
of the economic analysis or of the underlying question being
addressed.
Finally the JCVI makes a recommendation or provides advice.
A recommendation applies when the question has been asked of
the committee speciﬁcally by the Secretary of State for Health
and it applies to universal vaccination. This has speciﬁc implica-
tions as described above. Advice, rather than a recommendation,
is provided when such a question has not been asked, for exam-
ple where it is a change in indication or a modiﬁcation of existing
advice—or where the vaccination concerned is occupational or
for travellers. These latter two are not funded centrally by the
government—either the employer or the traveller themselvesmust
pay for the vaccine. In these cases the advice from the JCVI is simply
guidance.
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Table 2
Developing Human Papilloma Virus (HPV) vaccine advice.
1. New vaccines against HPV 16 and 18 were about to become available,
there were two potential vaccines: one bivalent and one quadrivalent
including HPV types that cause genital warts
2. Joint Committee on Vaccination and Immunisation (JCVI) established a
sub-committee of experts on HPV
3. Sub-committee reviewed published evidence, data from manufacturers
and worked with Health Protection Agency (HPA) surveillance and
infectious disease modellers to develop advice (3 meetings)
4. Sub-committee identiﬁed missing information
5. HPA collected data to ﬁll gaps on age speciﬁc information on acquisition
of HPV types 16 and 18 by single years of age from 12- to 25-year-old
girls [1]
6. HPA collected data on costs of treatment of genital warts [2]
7. HPA developed cost-effectiveness model of HPV vaccination in the
United Kingdom [3]
8. Cost-effectiveness model refereed, modiﬁed and submitted to main JCVI
9. JCVI agreed recommendation:
http://www.dh.gov.uk/prod consum dh/groups/dh digitalassets/@dh/@ab/
documents/digitalasset/dh 094739.pdf
5. Role played by economic evaluations and other ﬁnancial
issues in decision making
Cost-effectiveness is the cornerstone of decision making where
universal vaccination of the population is concerned since the costs
of the vaccination are borne by the Government through central
procurement of vaccines. The guidelines used by the committee
are that the vaccine should result in a cost of less than £20–30,000
per Quality Adjusted Life Year (QALY) gained. This is used across
the health policy making ﬁeld in the UK to ensure a balance in
preventative and treatment options available to the public. The
development of the cost-effectiveness data requires a combination
of economic cost data onvaccine, vaccinedelivery, illness anddeath
and mathematical modelling to capture potential herd immunity
effects. The perspective used is that of the NHS—so no societal costs
are included (such as loss of parental time at work). This leads
to some less serious infections, such as rotavirus and chickenpox,
where the burden fall largely on the family not reaching the cost-
effective threshold. The committee plays no role in procurement of
vaccine. It does not know the price of vaccines offered to the UK
nor what is ﬁnally agreed by the procurement process since this
is commercially conﬁdential (see case study on the HPV vaccine
advice in Table 2).
6. Role of manufacturers, and other private and
professional interest groups
Manufacturers do not attend JCVI nor sub-committees. They are
in regular contact with the secretariat in the Department of Health
and havemeetings to discuss developments and relationships. JCVI
has recently introduced the practice of asking manufacturers for
information directly when carrying out horizon scanning in order
to make this as complete as possible. When sub-committees meet
to discuss possible advice the industry is asked to provide writ-
ten information. This often includes unpublished and commercially
sensitive information. Industry has expressed a desire to havemore
input to the process and speciﬁcally to attend and present at sub-
committee meetings. However JCVI has so far not agreed to this.
Despite this situation some of the public and news media perceive
the committee as too inﬂuenced by the Pharmaceutical industry.
This perceptionarises fromthe fact that thepublicly listedpotential
conﬂicts of interest include funding for research from commer-
cial organisations. Although these potential conﬂicts of interest are
carefully handled in meetings to ensure that they do not inﬂuence
the advice provided.
Meetings of the JCVI and of sub-committees are closed. How-
ever observers are invited, and regularly attend, from the devolved
administrations in Wales, Scotland and Northern Ireland as well
as on occasion from Jersey and the Isle of Man. Also invited
as observers are representatives of the HPA, Health Protection
Scotland (HPS), the National Institute of Biological Standards and
Control (NIBSC which since April has been part of the HPA), MHRA.
The HPA is responsible for surveillance in England of vaccine pre-
ventable disease and carries out extensive work on the assessment
of vaccines both through observational studies and trials. In addi-
tion HPA carries out routine surveillance of adverse reactions with
speciﬁc research studies where necessary. This work is often done
in conjunction with the MHRA. HPS fulﬁls a similar role for Scot-
land. NIBSC is responsible for the testing and clearance of batches
of vaccine imported to the country and thus has exceptional knowl-
edgeandexperiencewith laboratory aspects of vaccines. TheMHRA
is responsible for monitoring of adverse reactions to medicines
including vaccines. They regularly report to the committee on these
data. Members of the public or representatives of public interest
groups are not admitted to JCVI or sub-committee meetings.
7. Communication activities and training practices
The agenda for JCVI meetings is placed on the public website
2 weeks in advance of each meeting. The minutes of each meet-
ing are also placed on the website within 6 weeks of each meeting
along with minutes of sub-committee meeting once ratiﬁed by the
sub-committee and JCVI. All JCVI advice is collaged into a publica-
tion – Immunisation against Infectious Disease (“the Green Book”).
This is edited by the Department of Health and members of the
Immunisation Division of the HPA. Although it is physically pub-
lished irregularly (the last edition was in 2006) every alteration
to the advice is posted on the website and a “patch” is provided
which can be printed and pasted into the hard copy of the book.
The chairman of the committee speaks on the work of the commit-
tee at meetings of Immunisation Coordinators in England annually
and when requested in Scotland, Wales and Northern Ireland.
8. Problems encountered, limitations and future
developments
The committee functionswell and ingeneral hasnothad speciﬁc
problems. A general concern has beenhowweensure that the com-
mittee keeps up to date with the latest evidence. There are many
vaccines involved in the programme and the committeewould like
to see any relevant evidence that might affect existing policy on
these at each meeting. However the volume of work in carrying
out rolling systematic reviews makes this impossible. Of course
the committee members are themselves all involved in vaccina-
tion – either research or programme delivery – and the secretariat
in Department of Health are constantly exposed to new informa-
tion, therefore the committee relies on these sources to keep the
committee up to date.
The committeewould ideally like each cost-effectiveness analy-
sis to be carried out by at least two groups using differentmethods.
This has occurredwith thework onmodelling of inﬂuenzaAH1N1v
epidemiologyandvaccination.However todo this for eachquestion
facing the committee is beyond the infectious disease modelling
capacity of the UK—although the UK is very well supplied with
such expertise. The growth of interest in this area of science and
the extensive training now ongoing should resolve this limitation
in time.
A result of the changes resulting from the NHS Constitution is
that we need to strengthen the committee in economics and infec-
tious disease modelling expertise. In addition the committee has
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been criticised for a lack of openness—this is a topic the committee
regularly reviews and plans to take steps to improve transparency
in the near future.
9. Summary and conclusions
JCVI is an independent committee which advises Ministers of
Health in the UK on vaccine policy. It has been successful in that
theGovernmenthas, to date, implemented the advice.However the
processes of the committee are constantly being criticised (unfairly
in the opinion of the committee, which is strongly protective of its
independence and regards it as vital to its role) either by the vaccine
industry for not allowing them sufﬁcient access to the committee
or by the public for being too inﬂuenced by the vaccine industry. In
addition there is constant pressure to increase openness and trans-
parency in the committee activities. This is likely to lead to changes
in thenear future, althoughensuring that any changesmade arenot
detrimental to its role and function.
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